HLS Therapeutics Inc (HLTRF) Financial Statements
0 Followers
HLS Therapeutics Inc Financial Overview
HLS Therapeutics Inc's market cap is currently $93.78M. The company's EPS TTM is $-0.27; its P/E ratio is -11.47; and it has a dividend yield of 3.44%. HLS Therapeutics Inc is estimated to report earnings on November 12, 2026, and the estimated EPS forecast is $-0.07. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 56.47M | $ 56.62M | $ 63.07M | $ 61.47M | $ 60.01M |
| Gross Profit | $ 24.01M | $ 47.62M | $ 55.45M | $ 56.49M | $ 56.04M |
| Operating Income | ― | $ -7.69M | $ -10.35M | $ -13.44M | $ -6.24M |
| EBITDA | $ 18.02M | $ 17.22M | $ 12.88M | $ 18.00M | $ 25.41M |
| Net Income | $ -12.65M | $ -19.66M | $ -27.53M | $ -23.60M | $ -13.12M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 11.70M | $ 17.46M | $ 21.95M | $ 20.72M | $ 21.18M |
| Total Assets | $ 137.28M | $ 159.90M | $ 209.06M | $ 241.65M | $ 275.90M |
| Total Debt | $ 49.73M | $ 66.45M | $ 87.62M | $ 97.34M | $ 97.57M |
| Net Debt | $ 38.03M | $ 48.99M | $ 65.67M | $ 76.62M | $ 76.39M |
| Total Liabilities | $ 75.72M | $ 88.56M | $ 111.36M | $ 116.33M | $ 115.17M |
| Stockholders' Equity | $ 61.56M | $ 71.34M | $ 97.70M | $ 125.32M | $ 160.74M |
| Cash Flow | |||||
| Free Cash Flow | $ 15.81M | $ 7.99M | $ 15.60M | $ 6.79M | $ 11.92M |
| Operating Cash Flow | $ 16.02M | $ 8.00M | $ 15.79M | $ 16.94M | $ 16.43M |
| Investing Cash Flow | $ -1.73M | $ 11.73M | $ -189.00K | $ -10.15M | $ -4.51M |
| Financing Cash Flow | $ -20.52M | $ -23.36M | $ -14.64M | $ -6.86M | $ -11.40M |
Currency in USD
